tlk1b Antibody

Overview of TLK1B Antibody

TLK1B antibodies are designed to recognize the TLK1B protein, which differs from TLK1 by alternative splicing of its mRNA, resulting in distinct regulatory regions. TLK1B is translationally regulated in response to DNA damage (e.g., ionizing radiation or doxorubicin) and plays a role in chromatin assembly and double-strand break (DSB) repair . The antibody is critical for:

• Detecting TLK1B expression via western blotting (WB) and immunofluorescence (IF) .

• Studying TLK1B’s phosphorylation targets, including histone H3 and the histone chaperone Asf1 .

DNA Damage Response and Repair

TLK1B antibodies have been instrumental in demonstrating the kinase’s role in DSB repair:

• Radioresistance: Overexpression of TLK1B accelerates repair of damaged episomes and genomic DNA, correlating with rapid dephosphorylation of γ-H2AX and histone H3 post-irradiation .

• Chromatin Remodeling: TLK1B phosphorylates Asf1, enhancing chromatin assembly at DSB sites. Nuclear extracts from TLK1B-expressing cells showed superior repair efficiency in in vitro assays .

Cell Cycle Regulation

• TLK1B antibodies revealed its interaction with NEK1, a kinase critical for ATR/Chk1-mediated cell cycle checkpoints. Depletion of TLK1B prolongs S-phase arrest after DNA damage .

• In prostate cancer models, TLK1B upregulation under androgen deprivation promotes survival via AKT activation and anti-apoptotic pathways .

Mechanisms of Action

• Phosphorylation Targets:

  • Histone H3 at Ser10, linked to chromatin relaxation during repair .

  • Asf1, enhancing histone deposition at DSB sites .

  • RAD54B and NEK1, facilitating homologous recombination repair (HRR) and checkpoint recovery .

• Translational Regulation:
  TLK1B synthesis is rapidly induced by DSBs via mTORC1-dependent polysomal redistribution of its mRNA, bypassing transcriptional delays .

Disease Relevance

• Cancer Resistance: Elevated TLK1B in breast and prostate carcinomas correlates with resistance to ionizing radiation and chemotherapeutics (e.g., doxorubicin) .

• Stem Cell Differentiation: TLK1 knockdown in mouse embryonic stem cells (ESCs) delays differentiation by sustaining pluripotency factors (Oct4, Nanog) .

Technical Considerations

• Specificity Challenges: Commercial antibodies often target shared regions between TLK1 and TLK1B. Studies using isoform-specific reagents (e.g., siRNA or CRISPR) are essential for functional validation .

• Functional Assays: TLK1B’s role in repair is validated via:

  • In vitro plasmid repair assays with recombinant TLK1B .

  • Clonogenic survival assays in TLK1B-overexpressing cells .

Future Directions

TLK1B antibodies remain pivotal for exploring:

• Synthetic lethality with BRCA mutations due to TLK1B’s interaction with APEX2 .

• Therapeutic targeting in TLK1B-overexpressing cancers .